Fair Value Measurements - Contingent Consideration (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | |||
|---|---|---|---|---|---|
Jan. 31, 2022 |
Mar. 31, 2022 |
Dec. 31, 2021 |
Oct. 06, 2021 |
Feb. 25, 2019 |
|
| Fair Value Measurements | |||||
| Contingent consideration under RPAs and CPPAs | $ 3,075 | $ 8,075 | |||
| Bioasis | Royalty Purchase Agreement | |||||
| Fair Value Measurements | |||||
| Changes in estimated fair value of contingent consideration | 0 | ||||
| Contingent consideration under RPAs and CPPAs | $ 100 | ||||
| Affitech | Commercial payment purchase agreement | |||||
| Fair Value Measurements | |||||
| Contingent consideration under RPAs and CPPAs | $ 3,000 | $ 8,000 | |||
| Amount of milestone payment | $ 5,000 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Changes in estimated fair value of contingent consideration. No definition available.
|
| X | ||||||||||
- Definition Decrease in contingent consideration due to milestone payment. No definition available.
|
| X | ||||||||||
- Definition Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|